Bempedoic acid - Esperion Therapeutics

Drug Profile

Bempedoic acid - Esperion Therapeutics

Alternative Names: ESP-55016; ETC-1002

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia
  • Phase II Dyslipidaemias; Hypertension

Most Recent Events

  • 01 Nov 2018 Efficacy data from the phase III CLEAR Wisdom trial in Hypercholesterolaemia released by Esperion Therapeutics
  • 01 Nov 2018 Pooled efficacy data from the phase III LDL-C lowering development programme of bempedoic acid released by Esperion
  • 28 Oct 2018 Esperion Therapeutics completes the phase III CLEAR Wisdom trial in Hypercholesterolaemia (Adjunctive treatment) in Germany, United Kingdom and USA (PO) (NCT02991118)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top